Medtronic's Reveal heart monitor is first implantable diagnostic to reach U.S. market.
This article was originally published in The Gray Sheet
MEDTRONIC's REVEAL HEART MONITOR IS FIRST IMPLANTABLE DIAGNOSTIC to reach the U.S. market, clearing FDA via 510(k) on Jan. 30. The device is available immediately at a list price of $2,950, although the company acknowledges that it could be weeks or months before marketing activities are in full swing.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.